Clinical Trials Directory

Trials / Completed

CompletedNCT01670721

Colorectal Cancer Metastatic

A Multicenter, Single Arm, Open Label Clinical Trial Evaluating Safety and Health Related Quality of Life of Aflibercept in Combination With Irinotecan/5-FU Chemotherapy (FOLFIRI) in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
175 (actual)
Sponsor
Sanofi · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Primary Objective: To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those evaluated in the VELOUR trial \[EFC10262, NCT00561470\]) according to side effects prevention and management guidelines. Secondary Objective: To document the Health-Related Quality of Life (HRQL) of aflibercept in this participant population.

Detailed description

Each participant was treated until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever come first). Participants were followed-up during treatment and for at least 30 days after its last study treatment (either Aflibercept or FOLFIRI) administration, up to a maximum of 6 months.

Conditions

Interventions

TypeNameDescription
DRUGAFLIBERCEPTPharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
DRUGIrinotecanPharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
DRUGFluorouracilPharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
DRUGLeucovorinPharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

Timeline

Start date
2012-08-01
Primary completion
2015-06-01
Completion
2015-06-01
First posted
2012-08-22
Last updated
2016-11-28
Results posted
2016-11-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01670721. Inclusion in this directory is not an endorsement.